Hollandbio welcomes MimeCure as new member

Hollandbio connects, represents and supports the Dutch life sciences & biotech sector. We are proud to represent a growing community of innovative companies, ranging from start-ups and scale-ups to established industry players. Today, we are pleased to welcome our newest member: MimeCure.

MimeCure is a Dutch biotech company developing a first-in-class regenerative therapy for chronic and progressive lung diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF). The company is based in the Netherlands and builds on academic research originating from the University of Groningen.

The company’s lead program, MC002, is based on an active fragment of the endogenous protein osteoglycin. Rather than targeting inflammation or fibrosis alone, MimeCure’s approach aims to restore the lung’s intrinsic regenerative capacity by promoting lung tissue repair. This regenerative mechanism differentiates MC002 from current standard-of-care therapies, which primarily slow disease progression without addressing the underlying loss of functional lung tissue.

MC002 is being developed as an inhaled therapy, allowing direct delivery to the lung while limiting systemic exposure. MimeCure combines expertise in pulmonary biology, regenerative pharmacology, and inhalation formulation to advance MC002 toward early clinical development. The company is currently progressing preclinical efficacy, mechanism-of-action studies, and formulation development to support first-in-human clinical trials.

MimeCure’s long-term vision is to contribute to a new generation of regenerative medicines for lung disease, addressing unmet medical needs in indications where current treatment options remain limited. The company actively collaborates with academic partners, clinical experts, and industry stakeholders to accelerate translation from fundamental biology to patient benefit.

By joining Hollandbio, MimeCure aims to connect with the broader Dutch life sciences ecosystem, exchange expertise, and contribute to the collective effort to strengthen innovation in biotechnology and regenerative medicine.

For more information, visit www.mimecure.com.